Business UpdateMay 28, 2026, 08:02 AM
Rhythm Pharma Publishes New Diagnostic Algorithm for BBS
AI Summary
Rhythm Pharmaceuticals, Inc. announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. This simplified algorithm, developed by a multidisciplinary group of international experts, is designed to reduce the time to an informed diagnosis of BBS by integrating advances in understanding the disease and genetic testing. The company funded the writing and editorial assistance for the publication, which aims to support earlier diagnosis and timely management for patients.
Key Highlights
- Rhythm Pharma announced publication of a new, evidence-based diagnostic algorithm for Bardet-Biedl syndrome (BBS).
- The algorithm, published in the American Journal of Medical Genetics, aims to reduce time to BBS diagnosis.
- It builds on original Beales' Criteria (1999) by integrating advances in understanding BBS and genetic testing.
- A multidisciplinary group of international experts and patient advocacy organizations contributed to the effort.
- The new algorithm provides diagnostic pathways applicable across all age groups and clinical presentations.
- The updated algorithm will be presented at Rhythm's inaugural MOMENTUM MC4R Pathway Summit on June 12.
- Rhythm Pharmaceuticals funded the writing and editorial assistance for the publication.
Price Impact
More from RYTM